Literature DB >> 18066616

Long-term results after dissection of positive thoracic lymph nodes in patients with esophageal squamous cell carcinoma.

Hideaki Shimada1, Shin-ichi Okazumi, Hisahiro Matsubara, Tooru Shiratori, Yasunori Akutsu, Yoshihiro Nabeya, Tooru Tanizawa, Kazuyuki Matsushita, Hideaki Hayashi, Kaichi Isono, Takenori Ochiai.   

Abstract

BACKGROUND: Although thoracic lymph node metastasis in patients with thoracic esophageal squamous cell carcinoma (SCC) has been reported to be a negative risk factor for long-term survival, only a few studies have evaluated the clinicopathologic difference between the impact of metastasis to the paraesophageal lymph nodes and to the nonparaesophageal lymph nodes. The purpose of this study was to evaluate surgical outcome after the clearance of metastatic thoracic lymph nodes.
METHODS: Retrospectively reviewed were 164 consecutive patients with thoracic esophageal SCC who had not had preoperative treatment and underwent surgery from 1980 to 2005 and were found to have thoracic lymph node metastases. Of these patients, 83 underwent surgery from 1980 to 1994 and 81 from 1995 to 2005. Univariate and multivariate analyses were performed to evaluate the impact of nonparaesophageal lymph node metastasis on survival.
RESULTS: Univariate analysis revealed that T3/T4 tumors and the presence of nonparaesophageal node metastases were associated with only a 20% overall five-year survival rate. The overall five-year survival for the most recent period was significantly better than for the former period (42% vs. 13%, p<0.01). Based on a multivariate analysis of prognostic impact of each nonparaesophageal node, the presence of metastatic subcarinal and/or posterior mediastinal nodes was an independent risk factor for reduced survival.
CONCLUSION: Surgical outcome for patients with thoracic esophageal cancer and metastatic thoracic lymph nodes has improved during the last 25 years. Although postoperative chemotherapy might improve survival, the presence of T3/T4 tumors and/or metastatic nonparaesophageal nodes were unfavorable factors for survival.

Entities:  

Mesh:

Year:  2007        PMID: 18066616     DOI: 10.1007/s00268-007-9213-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  18 in total

1.  Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.

Authors:  Jeeyun Lee; Kyoung-Eun Lee; Young-Hyuck Im; Won Ki Kang; Keunchil Park; Kwhanmien Kim; Young Mog Shim
Journal:  Ann Thorac Surg       Date:  2005-10       Impact factor: 4.330

2.  Results of a nationwide study on the three-field lymph node dissection of esophageal cancer.

Authors:  K Isono; H Sato; K Nakayama
Journal:  Oncology       Date:  1991       Impact factor: 2.935

3.  Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus.

Authors:  M S Bhansali; H Fujita; T Kakegawa; H Yamana; T Ono; S Hikita; Y Toh; T Fujii; U Tou; K Shirouzu
Journal:  World J Surg       Date:  1997 Mar-Apr       Impact factor: 3.352

4.  A comparison of chemotherapy and radiotherapy as adjuvant treatment to surgery for esophageal carcinoma. Japanese Esophageal Oncology Group.

Authors: 
Journal:  Chest       Date:  1993-07       Impact factor: 9.410

5.  Clinical benefits of steroid therapy on surgical stress in patients with esophageal cancer.

Authors:  H Shimada; T Ochiai; S Okazumi; H Matsubara; Y Nabeya; Y Miyazawa; M Arima; Y Funami; H Hayashi; A Takeda; Y Gunji; T Suzuki; S Kobayashi
Journal:  Surgery       Date:  2000-11       Impact factor: 3.982

6.  Unique distribution patterns of metastatic lymph nodes in patients with superficial carcinoma of the thoracic oesophagus.

Authors:  T Matsubara; M Ueda; T Abe; T Akimori; N Kokudo; T Takahashi
Journal:  Br J Surg       Date:  1999-05       Impact factor: 6.939

7.  Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers.

Authors:  Hideaki Shimada; Yoshihiro Nabeya; Hisahiro Matsubara; Shin-Ichi Okazumi; Tooru Shiratori; Takanori Shimizu; Taito Aoki; Kiyohiko Shuto; Yasunori Akutsu; Takenori Ochiai
Journal:  Am J Surg       Date:  2006-02       Impact factor: 2.565

8.  Radical lymph node dissection for cancer of the thoracic esophagus.

Authors:  H Akiyama; M Tsurumaru; H Udagawa; Y Kajiyama
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

9.  Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

Authors:  Nobutoshi Ando; Toshifumi Iizuka; Hiroko Ide; Kaoru Ishida; Masayuki Shinoda; Tadashi Nishimaki; Wataru Takiyama; Hiroshi Watanabe; Kaichi Isono; Norio Aoyama; Hiroyasu Makuuchi; Otsuo Tanaka; Hideaki Yamana; Shunji Ikeuchi; Toshiyuki Kabuto; Kagami Nagai; Yutaka Shimada; Yoshihide Kinjo; Haruhiko Fukuda
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

10.  Treatment response and prognosis of patients after recurrence of esophageal cancer.

Authors:  Hideaki Shimada; Hiroyuki Kitabayashi; Yoshihiro Nabeya; Shin-ichi Okazumi; Hisahiro Matsubara; Yutaka Funami; Yukimasa Miyazawa; Tooru Shiratori; Takashi Uno; Hisao Itoh; Takenori Ochiai
Journal:  Surgery       Date:  2003-01       Impact factor: 3.982

View more
  2 in total

1.  Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

Authors:  Junqing Liu; Yishuang Li; Ying Chen; Xue Jiang; Haogang Yu; Senxiang Yan
Journal:  Contrast Media Mol Imaging       Date:  2022-07-16       Impact factor: 3.009

2.  Feasibility and strategy for left tracheobronchial lymph node dissection in thoracolaparoscopic esophageal cancer surgery.

Authors:  Jiangbo Lin; Mingqiang Kang; Shuchen Chen; Fan Deng; Zhiyang Han; Jihong Lin
Journal:  Thorac Cancer       Date:  2015-09-16       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.